Data show how AbCellera is expanding the reach of T-cell
engagers with:
- CD3-binding antibodies that consistently generate T-cell
engagers with potent tumor-cell killing and low cytokine release
across multiple tumor targets, including PSMA, B7-H4, and 5T4
- Costimulatory CD28-binding antibodies that stimulate T cells
without superagonist activity
- Highly specific T-cell engagers for the peptide-MHC target
MAGE-A4
AbCellera (Nasdaq: ABCL) today announced new data on its T-cell
engager (TCE) programs at the American Association for Cancer
ResearchⓇ (AACR) Annual Meeting 2024 at the San Diego Convention
Center, with three posters being presented on April 8 and one on
April 9. Together, AbCellera’s data demonstrate that it is
well-positioned to advance TCEs as a drug class by widening the
therapeutic window, enhancing potency, and broadening the
accessible target space.
“TCEs are among the most promising new modalities in cancer
therapy, but limitations in efficacy and safety have been barriers
to realizing their potential for solid tumor indications,” said Bo
Barnhart, Ph.D., VP, Translational Research at AbCellera. “Our data
illustrate that we can repeatedly generate TCEs that maximize
tumor-cell killing without inducing excessive cytokine release.
Reducing the risk associated with CD3 engagement could improve
efficacy both by widening the therapeutic window and by creating
opportunities to further enhance potency through co-stimulatory
modalities.”
AbCellera’s poster presentations, which are available for
viewing here, describe how AbCellera is:
Widening the therapeutic window: AbCellera’s data
describe the generation of TCEs for three solid tumor targets,
PSMA, B7-H4, and 5T4, with functional profiles that are
differentiated from clinical benchmarks. These molecules were
engineered using a specific set of rare CD3-binding antibodies that
consistently show potent tumor-cell killing and low cytokine
release across multiple targets, demonstrating their potential to
expand the therapeutic window across solid tumor indications.
Enhancing potency: TCEs that engage the CD28
costimulatory receptor can enhance T-cell activation,
proliferation, and anti-tumor activities, particularly in solid
tumors. The data show that AbCellera’s IgG and heavy chain-only
CD28-binding antibodies do not display superagonist activity — a
property associated with toxicity. Integrating costimulatory
building blocks into AbCellera’s TCE repertoire may enable
development of molecules with enhanced potency for
difficult-to-treat cancers.
Broadening the accessible target space: The target
repertoire for TCEs has been restricted to proteins expressed on
the surface of cancer cells. Intracellular peptides displayed on
MHC class I (pMHCs) would greatly expand the target pool for TCEs.
However, development of TCEs against pMHCs has been limited due to
the high degree of target specificity required. Data illustrate how
AbCellera is unlocking this target class by generating molecules
with high specificity for MAGE-A4-pMHC, which showed little to no
binding to hundreds of off-target pMHCs.
“Our platform for creating precision TCEs to address indications
in cancer and autoimmunity provides a strong foundation for both
internal programs and strategic partnerships,” said Murray
McCutcheon, Ph.D., SVP, Partnering at AbCellera. “We look forward
to advancing these programs with the aim of delivering powerful new
medicines for patients.”
About AbCellera’s T-Cell Engager Platform
CD3 T-cell engagers have the potential to be a cornerstone of
cancer treatment. They guide the immune system to find and
eliminate cancer cells by binding the CD3 protein on cancer-killing
T cells and tumor targets at the same time. However, development of
T-cell engagers has been limited due to challenges with efficacy
and safety. To address these challenges, AbCellera developed a
T-cell engager platform that includes novel CD3-binding antibodies
to expand the therapeutic window for this modality, costimulatory
building blocks to enhance efficacy for difficult-to-treat cancers,
and discovery capabilities to broaden the range of T-cell engagers
to complex peptide-MHC tumor targets. AbCellera is leveraging its
platform to unlock the full potential of this modality and bring
powerful new cancer medicines to patients.
About AbCellera Biologics Inc.
AbCellera (Nasdaq: ABCL) discovers and develops antibody
medicines for indications across therapeutic areas including
cancer, metabolic and endocrine conditions, and autoimmune
disorders. AbCellera’s engine integrates technology, data science,
infrastructure, and interdisciplinary teams to solve the most
challenging antibody discovery problems. AbCellera is focused on
advancing an internal pipeline of first-in-class and best-in-class
programs and collaborating on innovative drug development programs
with partners. For more information, please visit
www.abcellera.com.
AbCellera Forward-Looking Statements
This press release contains forward-looking statements,
including statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. The
forward-looking statements are based on management’s current
beliefs and assumptions and on information currently available to
management. All statements contained in this release other than
statements of historical fact are forward-looking statements,
including statements regarding our ability to develop,
commercialize, and achieve market acceptance of our current and
planned products and services, our research and development
efforts, and other matters regarding our business strategies, use
of capital, results of operations and financial position, and plans
and objectives for future operations.
In some cases, you can identify forward-looking statements by
the words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties, and other factors that may cause
actual results, levels of activity, performance, or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties,
and other factors are described under “Risk Factors,” “Management's
Discussion and Analysis of Financial Condition and Results of
Operations,” and elsewhere in the documents we file with the
Securities and Exchange Commission from time to time. We caution
you that forward-looking statements are based on a combination of
facts and factors currently known by us and our projections of the
future, about which we cannot be certain. As a result, the
forward-looking statements may not prove to be accurate. The
forward-looking statements in this press release represent our
views as of the date hereof. We undertake no obligation to update
any forward-looking statements for any reason, except as required
by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240408026188/en/
Inquiries Media: Kathleen Reid; media@abcellera.com,
+1(236)521-6774 Business Development: Murray McCutcheon, Ph.D.;
bd@abcellera.com, +1(604)559-9005 Investor Relations: Melanie
Solomon; ir@abcellera.com, +1(778)729-9116
AbCellera Biologics (NASDAQ:ABCL)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
AbCellera Biologics (NASDAQ:ABCL)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024